Bayer to settle US-based lawsuits
While courts around the world argue through claims herbicide Roundup is carcinogenic, Bayer has agreed to pay out US$10.9 billion to settle US-based lawsuits.
A new ready-to-use antibiotic formulation for treating mastitis is now available for New Zealand dairy farmers.
Penethaject RTU (ready to use) took seven years to develop, register and launch; it has a unique formulation that requires no pre-mixing.
It’s the first time such a formulation has been developed anywhere in the world.
Bayer dairy veterinarian Dr Ray Castle says Penethaject RTU will make it easier for farmers to effectively treat clinical mastitis, a condition affecting 10-20% of NZ’s five million dairy cows every year.
“The active ingredient of Penethaject RTU, known as Penethamate, previously came in powder form and had to be mixed with a liquid by the farmer or veterinarian to create an injectable solution.
“Developing a pre-formulated version had been a scientific challenge for many years until scientists in Bayer NZ’s laboratories worked with Otago University to create a stable formulation, something that had never been achieved before.”
Castle says Penethamate is stable long term as a powder but not as a liquid.
“The challenge was to create a liquid formulation in which the active ingredient remained stable and active without caking or sticking together in clumps.”
To overcome the caking issue, Bayer worked with Otago University on adding different ingredients to stabilise the formulation, before finding a formulation that worked.
“The whole process, including clinical trials, stability testing, registration and commercial manufacturing, took about seven years. It’s a world-first and confirms NZ’s position as a leader in dairy science.”
Castle says the chemistry in Penethaject, a form of penicillin injected into the cow’s muscle, is so ‘clever’ that it allows antibiotic concentrations to build up in a cow’s udder. These concentrations are up to 10 times higher than those achieved by other penicillin formulations.
This allows the antibiotic to directly work on the mastitis bacteria, particularly Streptococcus uberis, the most common bacteria responsible for mastitis in NZ.
Once the mastitis is treated, the antibiotic quickly leaves the milk, allowing the cow to be back in milk production, in some cases within 48 hours.
Castle says farmers need to be particularly alert to the clinical signs of mastitis, which include changes in the colour and consistency of the milk, and/or redness, heat and swelling in the udder.
Penethaject RTU is a restricted veterinary medicine, and is only available under veterinary authorisation.
A brilliant result and great news for growers and regional economies. That's how horticulture sector leaders are describing the news that sector exports for the year ended June 30 will reach $8.4 billion - an increase of 19% on last year and is forecast to hit close to $10 billion in 2029.
Funding is proving crucial for predator control despite a broken model reliant on the goodwill of volunteers.
A major milestone on New Zealand's unique journey to eradicate Mycoplasma bovis could come before the end of this year.
We're working through it, and we'll get to it.
The debate around New Zealand's future in the Paris Agreement is heating up.
A technical lab manager for Apata, Phoebe Scherer, has won the Bay of Plenty 2025 Young Grower regional title.
OPINION: It's official, Fieldays 2025 clocked 110,000 visitors over the four days.
OPINION: The Federated Farmers rural advocacy hub at Fieldays has been touted as a great success.